Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Medicines After Kidney Transplant: What Studies Found

A review of nine retrospective studies included 338 kidney transplant recipients, most with diabetes. The studies offer limited evidence about long-term graft outcomes.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
What each population has behind itCKD, randomizedplacebo-controlledmedian 3.4 yearsAfter a transplant:Observationalcohort studiesThe studies enrolled different populations.Transplant care requires specialist follow-up.

Studies have examined GLP-1 medicines after kidney transplantation, mostly in people with diabetes. A review of nine retrospective studies covered 338 recipients, including 240 who received a GLP-1 medicine [3]. The evidence does not establish how well the results apply to people using these medicines solely for weight loss.

What transplant studies found

In one retrospective study of 39 recipients, mean HbA1c fell from 8.4% to 7.4% and mean weight from 99.5 kg to 90.7 kg at the 13- to 18-month assessment [2]. The study found no significant change in graft function markers. Without a randomized comparison, it cannot establish how much of the change came from semaglutide or rule out rare harms.

The nine-study review found no clear change in average tacrolimus levels. Gastrointestinal symptoms were the most commonly reported side effects [3]. The group average does not predict what will happen to an individual patient’s medication levels.

How the transplant evidence differs from FLOW

The pooled semaglutide kidney analysis includes FLOW, a randomized trial in people with type 2 diabetes and chronic kidney disease. A separate FLOW analysis examined results across categories of kidney function and urine albumin [1]. Transplant studies address a different population and have less evidence about long-term graft outcomes.

The transplant evidence remains observational. Your transplant team can explain how those findings apply to your care.

Frequently asked

What evidence is available after a kidney transplant?
A review included nine retrospective studies covering 338 kidney transplant recipients. Most participants had diabetes. The studies cannot establish long-term safety for individual patients.
What should I discuss with my transplant team?
Ask whether these medicines fit your treatment plan and what follow-up you would need for graft function, side effects and immunosuppressant levels.

Sources

  1. [1] Tuttle K, Mann J, Mayrdorfer M, Rayner B, et al. (2026). Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial Clinical Journal of the American Society of Nephrology. PMID 41706532
  2. [2] Mahzari M, Alluhayyan O, Almutairi M, Bayounis M, et al. (2024). Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes Journal of Clinical & Translational Endocrinology. PMID 38623181
  3. [3] Krisanapan P, et al. (2024). Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis Clinical Kidney Journal. PMID 38410684

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence